Anaplastic Lymphoma Kinase (ALK)-positive Tumors

Gupta, Rohan; Amanam, Idoroenyi; Rahmanuddin, Syed; Mambetsariev, Isa; Wang, Yingyu; Huang, Charity; Reckamp, Karen L.; Vora, Lalitkumar K.; Salgia, Ravi

doi:10.1097/coc.0000000000000508

American Journal of Clinical Oncology

2019

DOI: 10.1097/coc.0000000000000508

|View full text |Cite

Anaplastic Lymphoma Kinase (ALK)-positive Tumors

Rohan Gupta¹,

Idoroenyi Amanam²,

Syed Rahmanuddin

et al.

Abstract: Supplemental Digital Content is available in the text.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2023

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 45 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of the rarity of ALK-rearranged NSCLC, it is important to collect and evaluate data in clinical practice in addition to the results of clinical trials to evaluate its significance. ALK rearranged gene mutation is an oncogenic driver of NSCLC and commonly associated with younger age (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16). Although under a small number, however, elderly ALKrearranged NSCLC patients also have been reported (17)(18)(19).…”

mentioning

confidence: 99%

Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients

Miyazaki¹,

Sato²,

Kodama³

et al. 2020

In Vivo

View full text Add to dashboard Cite

Aim: To clarify the clinicopathological features in elderly anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) patients. Patients and Methods: A retrospective study was performed in 129 ALK rearranged NSCLC patients diagnosed between April 2008 and March 2019 in fifteen Institutions of the Ibaraki prefecture, Japan. Results: Median age of patients was 63 years. In 59 patients aged 65 and older, the proportions of patients with advanced stage and those treated with ALKtyrosine kinase inhibitor (TKI) were lower than those younger than 65 years. There was no difference in overall survival (OS) between the two age groups. Among the elderly patients, no difference was observed in OS between the patients aged 65-69 and those aged 70 and older. In 89 patients treated with TKI, no significant differences were observed in the progression-free survival of TKIs and OS between patients aged 65 and older and those younger than 65, respectively. Conclusion: Evaluation of ALK gene status and TKI treatment are desirable even for elderly patients. Advances in molecular biology have led to discovery of specific driver genes in certain cancer types and therefore to development of specific therapeutics (1, 2). This new trend is evident in the clinical practice of NSCLC patients. Mutations in the anaplastic lymphoma kinase (ALK) fusion gene is one such driver gene. Long-term survival can be expected in ALKrearranged NSCLC patients, but its frequency is very rare (1, 2001 This article is freely accessible online.

show abstract

mentioning

confidence: 99%

Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients

Miyazaki¹,

Sato²,

Kodama³

et al. 2020

In Vivo

View full text Add to dashboard Cite

show abstract

Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Guner¹,

Aktaş²,

Başal³

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Anaplastic Lymphoma Kinase (ALK)-positive Tumors

Abstract: Supplemental Digital Content is available in the text.

Cited by 6 publications

References 45 publications

Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients

Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients

Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer

Contact Info

Product

Resources

About